Donald James Tindall

Donald James Tindall's AcademicInfluence.com Rankings

Biology

#7474

World Rank

#10406

Historical Rank

Genetics

#720

World Rank

#812

Historical Rank

biology Degrees

Download Badge

Biology

Donald James Tindall's Degrees

PhD Genetics Stanford University

Why Is Donald James Tindall Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Donald James Tindall's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Effect of dutasteride on the risk of prostate cancer. (2010) (1063)
Dynamic FoxO transcription factors (2007) (1043)
Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. (2008) (819)
Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. (2007) (686)
Mechanisms of androgen-refractory prostate cancer. (2004) (564)
Androgen receptor signaling in androgen-refractory prostate cancer. (2001) (559)
FOXOs, cancer and regulation of apoptosis (2008) (539)
DHEA in elderly women and DHEA or testosterone in elderly men. (2006) (520)
Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated degradation. (2005) (499)
Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. (2002) (429)
Androgen receptor signaling in prostate cancer development and progression (2011) (426)
A novel human prostate-specific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer. (1997) (391)
Alternatively spliced androgen receptor variants. (2011) (349)
CDK2-Dependent Phosphorylation of FOXO1 as an Apoptotic Response to DNA Damage (2006) (324)
Molecular regulation of androgen action in prostate cancer (2006) (313)
Plk1-dependent phosphorylation of FoxM1 regulates a transcriptional programme required for mitotic progression (2008) (308)
Mutations in CHEK2 associated with prostate cancer risk. (2003) (299)
Hormonal regulation of prostate-specific antigen messenger RNA in human prostatic adenocarcinoma cell line LNCaP. (1991) (292)
Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. (2004) (285)
Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state. (2001) (274)
Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. (2004) (265)
Androgen transport and receptor mechanisms in testis and epididymis (1974) (251)
Androgen receptor structural and functional elements: role and regulation in prostate cancer. (2007) (248)
Regulation of the testis sertoli cell by follicle stimulating hormone. (1980) (241)
Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker. (1997) (240)
Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically. (2011) (234)
Follicle-stimulating hormone, the Sertoli cell, and spermatogenesis. (1976) (220)
p300 in prostate cancer proliferation and progression. (2003) (218)
Expression of early growth response genes in human prostate cancer. (1998) (204)
Tissue-specific and hormonal regulation of human prostate-specific glandular kallikrein. (1992) (204)
Activation of p73 silent allele in lung cancer. (1998) (199)
Hormonal regulation of prostate‐specific antigen (PSA) glycoprotein in the human prostatic adenocarcinoma cell line, LNCaP (1992) (193)
PTEN Induces Chemosensitivity in PTEN-mutated Prostate Cancer Cells by Suppression of Bcl-2 Expression* (2001) (193)
Androgen induction of a human prostate-specific kallikrein, hKLK2: characterization of an androgen response element in the 5' promoter region of the gene. (1993) (192)
Regulation of FOXO protein stability via ubiquitination and proteasome degradation. (2011) (189)
The role of androgens and the androgen receptor in prostate cancer. (2002) (184)
p300 mediates androgen-independent transactivation of the androgen receptor by interleukin 6. (2002) (179)
Prostate-specific antigen (PSA) promoter-driven androgen-inducible expression of sodium iodide symporter in prostate cancer cell lines. (1999) (178)
PTEN/MMAC1 mutations identified in small cell, but not in non-small cell lung cancers (1998) (176)
A frame-shift mutation in the androgen receptor gene causes complete androgen insensitivity in the testicular-feminized mouse. (1991) (160)
Overexpression of the wild type p73 gene in human bladder cancer (1999) (149)
Molecular mechanisms of androgen action. (1994) (149)
Minireview: Alternative activation pathways for the androgen receptor in prostate cancer. (2011) (148)
Use of human glandular kallikrein 2 for the detection of prostate cancer: preliminary analysis. (1999) (147)
Oxidative Stress and DNA Methylation in Prostate Cancer (2010) (144)
Androgen binding protein as a biochemical marker of formation of the blood-testis barrier. (1975) (139)
Isolation and androgen regulation of the human homeobox cDNA, NKX3.1 (1998) (136)
Hypermethylation of Genes for Diagnosis and Risk Stratification of Prostate Cancer (2009) (136)
Nonapoptotic cell death associated with S-phase arrest of prostate cancer cells via the peroxisome proliferator-activated receptor γ ligand, 15-deoxy-Δ12,14-prostaglandin J2 (2000) (136)
Global Methylation Profiling for Risk Prediction of Prostate Cancer (2012) (124)
Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases. (1999) (121)
Mechanisms for the testicular hypertrophy which follows hemicastration. (1978) (120)
Androgen deprivation increases p300 expression in prostate cancer cells. (2007) (116)
The role of the androgen receptor in prostate cancer. (2002) (115)
Selective clinical ultrasound signals mediate differential gene transfer and expression in two human prostate cancer cell lines: LnCap and PC-3. (1997) (115)
Metastatic prostate carcinoma to bone (2002) (115)
Epidermal growth factor induces cyclin D1 in a human prostate cancer cell line (1998) (112)
In situ hybridization of prostate-specific antigen mRNA in human prostate. (1990) (112)
PDLIM4 repression by hypermethylation as a potential biomarker for prostate cancer. (2006) (111)
The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer. (2008) (110)
Posttranslational Modification of the Androgen Receptor in Prostate Cancer (2013) (109)
The effects of growth factors associated with osteoblasts on prostate carcinoma proliferation and chemotaxis: implications for the development of metastatic disease. (1997) (109)
Endogenous cathepsin D-mediated hydrolysis of insulin-like growth factor-binding proteins in cultured human prostatic carcinoma cells. (1995) (108)
Ligand-independent Androgen Receptor Activity Is Activation Function-2-independent and Resistant to Antiandrogens in Androgen Refractory Prostate Cancer Cells* (2006) (107)
Type 1 and Type 2 5α-Reductase Expression in the Development and Progression of Prostate Cancer (2008) (105)
Are androgen receptor variants a substitute for the full-length receptor? (2015) (103)
HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study. (2016) (102)
Biochemical actions of follice-stimulating hormone in the sertoli cell of the rat testis. (1976) (102)
Workgroup 4: Spontaneous prostate carcinoma in dogs and nonhuman primates (1998) (100)
Androgen Receptor Upregulation Mediates Radioresistance after Ionizing Radiation. (2015) (98)
Regulation of androgen receptor signaling in prostate cancer (2005) (98)
Characterization of an early growth response gene, which encodes a zinc finger transcription factor, potentially involved in cell cycle regulation. (1995) (95)
Androgen regulation of gene expression. (2010) (95)
p300 regulates androgen receptor-independent expression of prostate-specific antigen in prostate cancer cells treated chronically with interleukin-6. (2005) (95)
FOXO factors: a matter of life and death. (2006) (89)
TGF-ß/Smad Signaling in Prostate Cancer (2003) (89)
Nonapoptotic cell death associated with S-phase arrest of prostate cancer cells via the peroxisome proliferator-activated receptor gamma ligand, 15-deoxy-delta12,14-prostaglandin J2. (2000) (88)
Selective role of an NH2-terminal WxxLF motif for aberrant androgen receptor activation in androgen depletion independent prostate cancer cells. (2007) (88)
Activation of P-TEFb by Androgen Receptor-Regulated Enhancer RNAs in Castration-Resistant Prostate Cancer. (2016) (87)
The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study. (2011) (86)
Molecular cloning of androgen receptors from divergent species with a polymerase chain reaction technique: complete cDNA sequence of the mouse androgen receptor and isolation of androgen receptor cDNA probes from dog, guinea pig and clawed frog. (1990) (86)
Loss of imprinting and allele switching of p73 in renal cell carcinoma (1998) (84)
Induction of prostatic intraepithelial neoplasia and modulation of androgen receptor by ETS variant 1/ETS-related protein 81. (2009) (82)
Noninvasive imaging and radiovirotherapy of prostate cancer using an oncolytic measles virus expressing the sodium iodide symporter. (2009) (82)
Autophagy control by the VEGF-C/NRP-2 axis in cancer and its implication for treatment resistance. (2013) (80)
Androgen Action in Prostate Cancer (2009) (80)
The role of PTEN in the progression and survival of prostate cancer. (2003) (80)
Calcium regulation of androgen receptor expression in the human prostate cancer cell line LNCaP. (1995) (78)
Differences in steroid specificity for rat androgen binding protein and the cytoplasmic receptor (1979) (77)
Androgen uptake and binding in rat epididymal nuclei, in vivo. (1972) (76)
New developments in the medical management of prostate cancer. (2010) (76)
Expression and significance of androgen receptor coactivators in urothelial carcinoma of the bladder. (2008) (73)
Androgen induction of the androgen receptor coactivator four and a half LIM domain protein-2: evidence for a role for serum response factor in prostate cancer. (2007) (73)
Effects of the calciotrophic peptides calcitonin and parathyroid hormone on prostate cancer growth and chemotaxis (1997) (73)
Androgens Negatively Regulate Forkhead Transcription Factor FKHR (FOXO1) through a Proteolytic Mechanism in Prostate Cancer Cells* (2004) (72)
Polycomb protein EZH2 suppresses apoptosis by silencing the proapoptotic miR-31 (2014) (72)
Expression of a prostate-associated protein, human glandular kallikrein (hK2), in breast tumours and in normal breast secretions (2000) (72)
Androgen receptors in rat testis. (1974) (72)
Expression of Immunosuppresive B7-H3 Ligand by Hormone-Treated Prostate Cancer Tumors and Metastases (2009) (72)
Androgen receptor splice variants bind to constitutively open chromatin and promote abiraterone-resistant growth of prostate cancer (2018) (71)
Modulation of Androgen Receptor by FOXA1 and FOXO1 Factors in Prostate Cancer (2014) (70)
p300 acetyltransferase regulates androgen receptor degradation and PTEN-deficient prostate tumorigenesis. (2014) (70)
Characterization of androgen receptor in Sertoli cell-enriched testis. (1977) (69)
Androgen modulation of coregulator expression in prostate cancer cells. (2009) (69)
Mechanism of lymph node metastasis in prostate cancer. (2010) (69)
Detection of circulating prostate cells by reverse transcriptase-polymerase chain reaction of human glandular kallikrein (hK2) and prostate-specific antigen (PSA) messages. (1997) (68)
The androgen receptor: a potential target for therapy of prostate cancer (2004) (68)
Characterization of human Sertoli cells in vitro. (1982) (65)
Expression and androgenic regulation of human prostate-specific kallikreins. (1995) (64)
The cistrome and gene signature of androgen receptor splice variants in castration resistant prostate cancer cells. (2015) (64)
Purification and characterization of androgen receptor from steer seminal vesicle. (1982) (63)
Structure and biochemistry of the Sertoli cell. (1985) (63)
p300 modulates nuclear morphology in prostate cancer. (2005) (62)
Vascular endothelial growth factor-C protects prostate cancer cells from oxidative stress by the activation of mammalian target of rapamycin complex-2 and AKT-1. (2009) (60)
Characterization of an androgen binding protein (ABP) in rat testis and epididymis. (1973) (60)
RhoA as a mediator of clinically relevant androgen action in prostate cancer cells. (2012) (59)
Isolation of cDNAs that are differentially expressed between androgen‐dependent and androgen‐independent prostate carcinoma cells using differential display PCR (1995) (57)
Detection of a prostate-specific protein, human glandular kallikrein (hK2), in sera of patients with elevated prostate-specific antigen levels. (1997) (57)
Antagonism of androgen action in prostate tumor cells by retinoic acid (1994) (56)
Tumor-promoting phorbol ester down-regulates the androgen induction of prostate-specific antigen in a human prostatic adenocarcinoma cell line. (1992) (56)
A comparison of the adrenal responses to hypoglycemia, metyrapone and ACTH (1978) (55)
A tyrosine aminotransferase glucocorticoid response element also mediates androgen enhancement of gene expression. (1989) (54)
Targeting 5α-reductase for prostate cancer prevention and treatment (2011) (54)
Type 1 and type 2 5alpha-reductase expression in the development and progression of prostate cancer. (2008) (54)
Purification and characterization of the androgen receptor from rat ventral prostate. (1983) (53)
Regulation of the 5'-flanking region of the mouse androgen receptor gene by cAMP and androgen. (1993) (53)
Kininogenase activity of prostate-derived human glandular kallikrein (hK2) purified from seminal fluid. (1999) (53)
Interactive effects of triiodothyronine and androgens on prostate cell growth and gene expression. (1999) (52)
Steroid 5 α-reductase inhibitors targeting BPH and prostate cancer (2011) (51)
Expression of human prostate-specific glandular kallikrein protein (hK2) in the breast cancer cell line T47-D. (1997) (49)
Androgens repress Bcl-2 expression via activation of the retinoblastoma (RB) protein in prostate cancer cells (2004) (49)
Novel Molecular Targets of Azadirachta indica Associated with Inhibition of Tumor Growth in Prostate Cancer (2011) (49)
Preliminary characterization of a binding protein for androgen in rabbit serum. Comparison with the testosterone-binding globulin (TeBG) in human serum. (1974) (49)
Highly sensitive automated chemiluminometric assay for measuring free human glandular kallikrein-2. (1999) (48)
Letter to the Editor: Androgens and Prostate Cancer: Are the Descriptors Valid? (2005) (46)
Concerning the hormonal regulation of androgen binding protein in rat testis. (1976) (46)
Androgen receptor: past, present and future. (2013) (46)
Identification of a novel complex between human kallikrein 2 and protease inhibitor-6 in prostate cancer tissue. (1999) (45)
FAVL elevation in human tumors disrupts Fanconi anemia pathway signaling and promotes genomic instability and tumor growth. (2010) (45)
Androgen-binding proteins in rat epididymis: properties of a cytoplasmic receptor for androgen similar to the androgen receptor in ventral prostate and different from androgen-binding protein (ABP) (1975) (44)
Identification of a clinically relevant androgen-dependent gene signature in prostate cancer. (2011) (43)
The androgen receptor of the testicular-feminized (Tfm) mutant mouse is smaller than the wild-type receptor. (1989) (43)
CBP loss cooperates with PTEN haploinsufficiency to drive prostate cancer: implications for epigenetic therapy. (2014) (42)
Gene expression in prostate cancer cells treated with the dual 5 alpha-reductase inhibitor dutasteride. (2004) (41)
Tyrphostin AG825 triggers p38 mitogen-activated protein kinase-dependent apoptosis in androgen-independent prostate cancer cells C4 and C4-2. (2001) (41)
Androgen action during prostate carcinogenesis. (2011) (41)
Follicle stimulating hormone regulation of protein kinase activity and protein synthesis in testis. (1976) (41)
Further studies on the accumulation and binding of androgen in rat epididymis. (1974) (41)
Mutation and expression analysis of the p73 gene in prostate cancer (1999) (40)
The Androgen Receptor Is Transcriptionally Suppressed by Proteins That Bind Single-stranded DNA (*) (1995) (39)
TGF-betal/Smad signaling in prostate cancer. (2003) (39)
Expression of androgen receptor protein within the lumbar spinal cord during ontologic development and following antiandrogen induced cryptorchidism. (1994) (38)
A critical evaluation of the use of androgen receptor assays to predict the androgen responsiveness of prostatic cancer. (1987) (38)
Flutamide-induced cryptorchidism in the rat is associated with altered gubernacular morphology. (1995) (37)
Inverse Association between Prostate Cancer and the Use of Calcium Channel Blockers (2004) (37)
Loss of NKX3.1 favors vascular endothelial growth factor-C expression in prostate cancer. (2008) (37)
Modulation of androgen receptor transcriptional activity by the estrogen receptor. (1994) (36)
Identification and characterization of a suppressor element in the 5'-flanking region of the mouse androgen receptor gene. (1994) (36)
Prostate-specific antigen and prostatic acid phosphatase: biomolecular and physiologic characteristics. (1991) (36)
Mutation analysis of the putative tumor suppressor PTEN/MMAC1 in human ovarian cancer. (1998) (36)
Transcriptional regulation of the steroid receptor genes. (1998) (36)
Detection of metastatic prostate cancer using a splice variant-specific reverse transcriptase-polymerase chain reaction assay for human glandular kallikrein. (2000) (36)
Antiangiogenic Effects and Therapeutic Targets of Azadirachta indica Leaf Extract in Endothelial Cells (2012) (36)
Prostate‐specific human kallikrein (hK2) as a novel marker for prostate cancer (1996) (35)
Hormonal Regulation of Sertoli Cells (1978) (35)
Unraveling the complexities of androgen receptor signaling in prostate cancer cells. (2009) (35)
A common molecular weight of the androgen receptor monomer in different target tissues. (1987) (34)
Regulation of expression of the early growth response gene‐1 (EGR‐1) in malignant and benign cells of the prostate (2005) (34)
Monoclonal antibodies against the androgen receptor: recognition of human and other mammalian androgen receptors. (1988) (34)
Gene silencing for epidermal growth factor receptor variant III induces cell-specific cytotoxicity (2008) (34)
The mouse androgen receptor gene contains a second functional promoter which is regulated by dihydrotestosterone. (1994) (32)
The role of the transcriptional coactivator p300 in prostate cancer progression. (2008) (31)
The production of androgen binding protein by Sertoli Cells. (1974) (31)
Steroid structural requirements for high affinity binding to human sex steroid binding protein (SBP) (1981) (31)
Androgen regulation of gene expression (1996) (31)
Overexpression of a human prostate-specific glandular kallikrein, hK2, in E. coli and generation of antibodies (1995) (30)
Responses of NBT-II bladder carcinoma cells to conditioned medium from normal fetal urogenital sinus. (1987) (30)
Androgen receptor abnormalities in castration-recurrent prostate cancer (2009) (29)
5alpha-Dihydrotestosterone binding to androgen binding protein. Effects of testosterone and other compounds in vivo and in vitro on the number of binding sites measured. (1978) (29)
Androgens regulate the expression of proliferating cell nuclear antigen posttranscriptionally in the human prostate cancer cell line, LNCaP. (1996) (29)
Deficiencies in Chfr and Mlh1 synergistically enhance tumor susceptibility in mice. (2009) (29)
Preclinical Evaluation of the Supercritical Extract of Azadirachta Indica (Neem) Leaves In Vitro and In Vivo on Inhibition of Prostate Cancer Tumor Growth (2014) (29)
TWIST1, A novel androgen-regulated gene, is a target for NKX3-1 in prostate cancer cells (2013) (29)
Identification of human glandular kallikrein hK2 from LNCaP cells. (1996) (28)
Androgen antagonists in androgen target tissues. (1984) (28)
The mouse androgen receptor is suppressed by the 5'-untranslated region of the gene. (1994) (28)
Defeating prostate cancer: Crucial directions for research—excerpt from the report of the Prostate Cancer Progress Review Group (1999) (28)
Affinity labeling of the androgen receptor in rat prostate cytosol with 17 beta-[(bromoacetyl)oxy]-5 alpha-androstan-3-one. (1984) (28)
Overexpression of a partial human androgen receptor in E. coli: characterization of steroid binding, DNA binding, and immunological properties. (1990) (28)
Effects of sodium molybdate on the androgen receptor from the R3327 prostatic tumor. (1984) (27)
CDK2 and FOXO1: A Fork in the Road for Cell Fate Decisions (2007) (27)
Differential regulation of steroid nuclear receptor coregulator expression between normal and neoplastic prostate epithelial cells (2010) (27)
Physicochemical characterization of the androgen receptor in rat uterine cytosol. (1983) (27)
The cytoskeleton differentially localizes the early growth response gene-1 protein in cancer and benign cells of the prostate. (2004) (26)
Hormonal regulation of androgen-binding protein in hypophysectomized rats. (1978) (26)
Reduced tumor necrosis factor receptor-associated death domain expression is associated with prostate cancer progression. (2009) (26)
Induction of FLIP expression by androgens protects prostate cancer cells from TRAIL‐mediated apoptosis (2008) (25)
Inhibition of fatty acid synthase activity in prostate cancer cells by dutasteride (2007) (25)
Alterations in maternal epidermal growth factor (EGF) effect testicular descent and epididymal development. (1994) (24)
Robust prostate-specific expression for targeted gene therapy based on the human kallikrein 2 promoter. (2001) (24)
Transgenic mice carrying a PSArasT24 hybrid gene develop salivary gland and gastrointestinal tract neoplasms. (1995) (24)
Androgens repress expression of the f‐box protein Skp2 via p107 dependent and independent mechanisms in LNCaP prostate cancer cells (2012) (24)
Properties of an intermediate-sized androgen receptor: association with RNA. (1986) (24)
Exchange assay for androgen receptors in the presence of molybdate. (1984) (23)
Estradiol-17 β inhibition of androgen uptake, metabolism and binding in epididymis of adult male rats in vivo: A comparison with cyproterone acetate (1981) (22)
Gluthatione-S-transferase P1 polymorphism I105V in familial and sporadic prostate cancer. (2004) (22)
The androgen receptor in the testicular feminized (Tfm) mouse may be a product of internal translation initiation. (1994) (22)
The effects of androgen administration on phallic androgen receptor expression. (1996) (21)
Metabolism of progesterone-4 14 C in porcine uterine endometrium. (1971) (21)
The Rationale for Inhibiting 5 α - Reductase Isoenzymes in the Prevention and Treatment of Prostate Cancer (2009) (20)
Properties and hormonal regulation of androgen binding proteins. (1980) (20)
Prostate cancer cells use genetic and epigenetic mechanisms for progression to androgen independence (2006) (19)
Unique substitution of CHEK2 and TP53 mutations implicated in primary prostate tumors and cancer cell lines (2006) (19)
Effects of the 5 alpha‐reductase inhibitor dutasteride on gene expression in prostate cancer xenografts (2009) (18)
DHEA in elderly women and DHEA or testosterone in elderly men (2007) (17)
Clathrin gene expression is androgen regulated in the prostate. (1998) (17)
Differential expression and allelotyping of the p73 gene in neuroblastoma. (2000) (17)
Identification and Characterization of a Consensus DNA Binding Element for the Zinc Finger Transcription Factor TIEG/EGRα (2003) (16)
FURTHER ANALYSES FROM THE REDUCE PROSTATE CANCER RISK REDUCTION TRIAL (2009) (16)
A novel yeast expression system to study androgen action. (1994) (16)
Advances in Brief p 300 in Prostate Cancer Proliferation and Progression (2003) (16)
FSH-induction of androgen binding protein in testes of Sertoli cell-only rats. (1975) (15)
Structural Requirements for Steroid Binding to Androgen Binding Proteins (1978) (15)
Androgenic regulation of luteinizing hormone secretion: relationship to androgen binding in sheep pituitary. (1987) (15)
Epidermal growth factor reverses antiandrogen induced cryptorchidism and epididymal development. (1994) (15)
Characterization of steroid binding specificity of the androgen receptor in human foreskin fibroblasts (1983) (14)
Mechanism of Action of FSH in the Male Rat (1978) (14)
Decline in the overall incidence of regional‐distant prostate cancer in Olmsted County, MN, 1980–2000 (2005) (14)
Identification and characterization of a consensus DNA binding element for the zinc finger transcription factor TIEG/EGRalpha. (2003) (13)
Symposium on Androgen Action in Prostate Cancer (2004) (12)
Micropenis in hypogonadotropic hypogonadism: response of the penile androgen receptor to testosterone treatment. (1998) (12)
Independent Prostate Cancer Cells − Androgen Receptor Activation in Androgen Depletion-Terminal WxxLF Motif for Aberrant 2 Selective Role of an NH Updated (2007) (11)
Androgens regulate TRAIL-induced cell death in prostate cancer cells via multiple mechanisms. (2013) (11)
Characterization of penile androgen receptor expression in micropenis due to hypogonadotropic hypogonadism. (1998) (11)
Selective Role of an NH 2-Terminal WxxLF Motif for Aberrant Androgen Receptor Activation in Androgen Depletion – Independent Prostate Cancer Cells (2007) (10)
Truncating variants in p53AIP1 disrupting DNA damage-induced apoptosis are associated with prostate cancer risk. (2006) (10)
Factors affecting Sertoli cell function in the testis. (1981) (10)
Abstract 2924: Constitutively active androgen receptor splice variants function independently of full-length androgen receptor in a cell-based model of castrate-resistant prostate cancer (2012) (10)
Use of tumor dynamics to clarify the observed variability among biochemical recurrence nomograms for prostate cancer (2012) (10)
Androgen receptors in prostate and skeletal muscle. (2000) (10)
Prostate Cancer: Cellular and Genetic Mechanisms of Disease Development and Progression (2019) (10)
Evaluation of familial clustering of breast and prostate cancer in the Minnesota Breast Cancer Family Study. (2003) (9)
LY191704 inhibits type I steroid 5 alpha-reductase in human scalp. (1996) (9)
Of mice, men, and hormones. (2004) (9)
State of research for prostate cancer: Excerpt from the report of the Prostate Cancer Progress Review Group. (2001) (8)
Expression of Immunosuppresive B 7-H 3 Ligandby Hormone-Treated Prostate Cancer Tumors andMetastases (2009) (7)
Transformation of NIH 3T3 cells by enhanced PAR expression. (2004) (7)
DETECTION OF PROSTATE CANCER WITH %FPSA AND HK2 WHEN PSA IS 2-4 NG/ML (1999) (7)
CHAPTER 10 – Androgen Receptor Protein: Purification and Molecular Properties (1986) (6)
Nuclear Receptor Coregulators: Promising Therapeutic Targets for the Treatment of Prostate Cancer (2010) (6)
Prostate Cancer (2013) (6)
Modeling and analysis of Gleason score 8-10 prostate cancers in the REDUCE study. (2014) (6)
Ligand Dependent and Independent Activation of the Androgen Receptor (2001) (5)
Introduction: Proper nomenclature facilitates clinical and translational research in prostate cancer (2009) (5)
Molecular Properties of the Androgen Receptor in Rat Ventral Prostate a (1984) (5)
Whole blood defensin mRNA expression is a predictive biomarker of docetaxel response in castration-resistant prostate cancer (2015) (4)
Androgen transport and receptor mechnisms in testis and epididymis. (1974) (4)
Recent advances in prostate cancer: Basic science discoveries and clinical advances (2011) (4)
Molecular and Cellular Biology of Prostate Cancer (2012) (4)
Characterization of a TPA-response element in the 5'-flanking region of the androgen receptor gene. (1998) (4)
Androgen Mediation—and Antiandrogens Mitigation—of the Epidermal Growth Factor Receptor (EGFR) Inhibitor–Induced Rash: Results From a Pilot Randomized Trial and Small Translational Case Series (2019) (4)
Epididymal androgen binding protein in protein-calorie malnourished rats. (1980) (4)
Physicochemical characterization of the androgen receptor from hyperplastic human prostate. (1985) (3)
Pursuing the androgen pathway on the quest to control prostate cancer (2007) (3)
Dihydrotestosterone synthesis from adrenal precursors does not involve testosterone in castration-resistant prostate cancer (2012) (3)
[22] Use of PCR in analysis of 5′-flanking region of androgen receptor gene (1995) (2)
TWIST, A NOVEL ANDROGEN-REGULATED GENE IS A TARGET FOR NKX3.1 IN PROSTATE CANCER CELLS (2006) (2)
Loss of NKX 3 . 1 Favors Vascular Endothelial Growth Factor-C Expression in Prostate Cancer (2008) (2)
Molecular progression of prostate cancer: Androgens and estrogens (2012) (2)
Molecular Biology of Prostate-Specific Antigen (1991) (2)
Introduction to manuscript by Prof. Donald S. Coffey (2014) (2)
Cells Treated Chronically with Interleukin-6 Expression of Prostate-Specific Antigen in Prostate Cancer Independent − p 300 Regulates Androgen Receptor (2005) (2)
Comprar Androgen Action in Prostate Cancer | Tindall, Donald | 9780387691770 | Springer (2009) (2)
162. Inhibition of uptake, metabolism and binding of androgen in epididymis of male rats in vivo: Comparison of estradiol and cyproterone acetate (1974) (2)
Androgen induction of the androgen receptor co-activator FHL2 : Evidence for a role for serum response factor in prostate cancer (2007) (2)
Imaging , Diagnosis , Prognosis Global Methylation Pro fi ling for Risk Prediction of Prostate Cancer (2012) (1)
Parting messages from current and former editors of the Journal of Andrology. (2012) (1)
7006 Effect of baseline characteristics on prostate cancer rates and risk reduction in the Reduction by Dutasteride of prostate Cancer Events REDUCE) trial (2009) (1)
611: Gene Expression Profile of Prostate Cancer Cells Treated with the Dual 5 Alpha-Reductase Inhiditor Dutasteride (2004) (1)
Relationship between ligand structure and affinity for androgen binding protein (1985) (1)
Impact of beta-blocker medication use on prostate cancer survival: Results from a single-institution cancer registry. (2014) (1)
Serum human glandular kallikrein 2 (HK2) concentration at presentation and early subsequent follow-up for patients undergoing primary radiotherapy or brachytherapy with or without androgen deprivation therapy for localized prostate cancer therapy (2004) (1)
Tumor and Stem Cell Biology p 300 Acetyltransferase Regulates Androgen Receptor Degradation and PTEN-De fi cient Prostate Tumorigenesis (2014) (1)
PtdIns 3-kinase (2011) (1)
The role of androgen receptor-regulated genes in prostate cancer progression (2014) (1)
Models Systems for the Study of Androgen-Regulated Gene Expression in the Central Nervous System (2002) (1)
Endocrine Mechanisms, Androgen Receptor and Carcinogenesis, and Hormone Escape (2013) (1)
Pancreas Cancer Molecular Targets for Therapy (2011) (1)
INFLUENCE OF BASELINE PATIENT CHARACTERISTICS ON THE INCIDENCE OF HIGH-GRADE (GLEASON SCORE ≥7) BIOPSY-DETECTABLE PROSTATE CANCER EVENTS IN THE REDUCTION BY DUTASTERIDE OF PROSTATE CANCER EVENTS (REDUCE) TRIAL (2009) (1)
TWIST1, A novel androgen-regulated gene, is a target for NKX3-1 in prostate cancer cells (2013) (1)
The Coactivators CBP and p300 in Androgen Independent Prostate Cancer (2005) (1)
Ligand-independent androgen receptor activity (2009) (1)
1296 LOGISTIC REGRESSION MODELING OF FACTORS AFFECTING RATES OF HIGH GRADE PROSTATE CANCER IN THE REDUCTION BY DUTASTERIDE OF PROSTATE CANCER EVENTS (REDUCE) STUDY (2011) (0)
Abstract 3304: Role of Vascular Endothelial Growth Factor C in promoting radioresistance of prostate cancer (2015) (0)
WITHDRAWN: Introduction to manuscript by Prof. Donald S. Coffey (2014) (0)
Steroid specificity of human testosterone-estrogen binding globulin (TeBG), androgen binding protein (ABP), and rat cytoplasmic receptor (CR) (1978) (0)
Purification and characterization of androgen receptor in rat skeletal muscle (1981) (0)
A comparison of purified androgen receptors from Dunning prostatic tumor and normal rat ventral prostate (1982) (0)
959 EFFECT OF BASELINE PROSTATE CANCER RISK ON DUTASTERIDE EFFICACY IN THE REDUCE (REDUCTION BY DUTASTERIDE OF PROSTATE CANCER EVENTS) STUDY (2010) (0)
Molecular Oncology: Prostate cancer (2013) (0)
Can etics Reduced Tumor Necrosis Factor Receptor – Associated Death Domain Expression Is Associated with Prostate Cancer Progression (2009) (0)
OP1-09 GENOME-WIDE ANALYSIS OF ANDROGEN RECEPTOR SPLICE VARIANTS BINDING AND GENE REGULATION IN CASTRATION-RESISTANT PROSTATE CANCER (2014) (0)
Role of the Androgen Receptor and PI3K/Akt in the Survival of Androgen-Refractory Prostate Cancer Cells (2005) (0)
Inhibitionof FattyAcid SynthaseActivity in Prostate CancerCellsbyDutasteride (2007) (0)
Identification andcharacterization ofa suppressorelement inthe5'-flanking region ofthemouse androgen receptor gene (1994) (0)
581 β2-adrenergic receptor regulation in prostate cancer upon androgen deprivation (2004) (0)
Androgen receptors in prostate and skeletal muscle. Discussion (2000) (0)
Primary Cancer Site (2011) (0)
1981 UTILITY OF COMBINING FINAL PSA AND PSA DYNAMICS (CHANGE FROM MONTH 6 TO FINAL PSA) FOR PROSTATE CANCER AND HIGH GRADE CANCER DIAGNOSIS IN THE REDUCTION BY DUTASTERIDE OF PROSTATE CANCER EVENTS (REDUCE) STUDY (2010) (0)
Hormones and Cancer Reviewers (2011) (0)
241PDTreatment of locally recurrent prostate cancer following external beam radiotherapy or brachytherapy: In situ gene therapy with iodine-131 and the sodium iodide symporter gene (2015) (0)
Prostate Cancer Therapy Resistance Constitutively Active Androgen Receptor that Mediates Exon Generates a Androgen Receptor Splicing of a Novel Updated (2008) (0)
Abstract 2318:Azadirachta indicaleaf extract attenuates angiogenesis in endothelial cells (2012) (0)
Relationship to Androgen Binding in Sheep Pituitary1 (1987) (0)
Androgen receptors in testicular Sertoli cells (1975) (0)
Androgen Receptor Signaling in Castration Resistant Prostate Cancer (2016) (0)
The influence of unscheduled biopsies on prostate cancer detection in the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial. (2016) (0)
SERTOLI CELL BY FOLLICLE STIMULATING HORMONE (1980) (0)
EFFECTS OF TESTOSTERONE AND OTHER COMPOUNDS IN VIVO AND Zh7 VITRO ON THE NUMBER OF BINDING SITES MEASURED (1977) (0)
Abstract 940: Inhibition of androgen receptor activity in refractory prostate cancer cells by the novel Millennium-Takeda compound T-1759243 (2012) (0)
Isolation of Differentially Expressed cDNAs from Prostate Cancer Cell Lines Using Differential Display PCR: Identification of an Androgen-Regulated Gene (1996) (0)
983 UTILITY OF COMBINING FINAL PSA AND PSA DYNAMICS (CHANGE FROM MONTH 6 TO FINAL PSA) FOR PROSTATE CANCER AND HIGH GRADE CANCER DIAGNOSIS IN THE REDUCE STUDY (2010) (0)
Steroid specificity of human testosterone-estrogen binding globulin (TeBG) and rat cytoplasmic receptor (CR) (1979) (0)
823 Serum Human Glandular Kallikrein 2 (Hk2) and Pro-Hk2 Concentration Changes Compared to Prostate Specific Antigen in Patients Undergoing Primary Radiotherapy or Brachytherapy (2007) (0)
Prostate Cancer Hormonal Therapy (2014) (0)
UP-2.169: A Phase I Clinical Trial of In Situ Gene Therapy with Radioiodine for Locally Recurrent Prostate Cancer Following External Beam Radiotherapy (2009) (0)
PROC. V. INT. CONGR. ENDOCRINOLOGY, VOL. I (1977) (0)
Prostate-specific Antigen ( PSA ) Promoter-driven Androgen-inducible Expression of Sodium Iodide Symporter in Prostate Cancer Cell Lines 1 (2000) (0)
Purification of the Androgen Receptor (1990) (0)
Abstract CN08-01: Targeting the androgen receptor in castration-resistant prostate cancer. (2011) (0)
Advances in Brief Disruption of Androgen Receptor Function Inhibits Proliferation of Androgen-refractory Prostate Cancer Cells 1 (2002) (0)
Silencing EGFRvIII as a therapeutic strategy against glioma (2007) (0)
Abstract 3950: Neuropilin-2, a transmembrane glycoprotein receptor, protects prostate cancer cells from stress (2010) (0)
Prostate Cancer Cells through a Proteolytic Mechanism in Transcription Factor FKHR (FOXO1) Androgens Negatively Regulate Forkhead Mechanisms of Signal Transduction (2014) (0)
Dual 5α-reductase inhibitor, dutasteride, inhibits androgen action, cell growth/viability in prostate cancer cell lines (2003) (0)
The androgen receptor (2011) (0)
S1 Molecular Mechanisms of Prostate Cancer Cell Survival following Androgen Ablative Therapy (2006) (0)
Increased screening, effective treatments, and overall decline in the community incidence of regional-distant prostate cancer (2004) (0)
Antibodies which are specific to human prostate kallikrein (1994) (0)
Renaturation of the androgen receptor after denaturation in SDS (1986) (0)
Comparison of hk2, pro-hk2 Failure With Conventional PSA Failure in Permanent Brachytherapy and External Beam Prostate Cancer Patients in a Prospective Biomarker Protocol (2007) (0)
861: Serum Human Glandular Kallikrein 2 and Pro-Human Glandular Kallikrein 2 Concentration Correlates with Survival in Patients with Hormone Refractory Prostate Cancer (2006) (0)
Abstract #5268: TRADD expression is critical for the down-regulation of androgen receptor induced by tumor necrosis factor alpha (2009) (0)
Abstract 109: DNA methylation profiling associated with recurrence of prostate cancer (2011) (0)
Purification of androgen receptor from rat prostate (1981) (0)
Abstract A8: Androgen regulation of SRF target genes in prostate cancer cells is mediated in part by the small GTPase RhoA (2012) (0)
The predictive value of HGPIN and ASAP for the subsequent diagnosis of prostate cancer in the Reduction by Dutasteride of Cancer Events (REDUCE) study. (2010) (0)
Abstract 89: Pin1 suppresses androgen receptor activity (2015) (0)
Population Candidate Gene Association Study (2011) (0)
Polypeptide hk2 recombine (1995) (0)
Role of PI3K–Akt and PTEN in the Growth and Progression of Prostate Cancer (2008) (0)
Androgen receptor action in the central nervous system (2009) (0)
Editorial Commentary on Zhu et al (2005) (0)
Abstract 4950: Correlation of methylation status with expression levels of the genes in prostate cancer (2010) (0)
EXCERPTA MEDICA, AMSTERDAM, ICS (1977) (0)
Molecular Biology of Androgen Receptors in Prostate Cancer Cells (1991) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Donald James Tindall?

Donald James Tindall is affiliated with the following schools: